Are There Any Side Effects Associated with Third-generation TKIs?
Like all cancer treatments, third-generation TKIs such as osimertinib come with potential side effects. Common side effects include diarrhea, rash, dry skin, and fatigue. More serious but less common side effects can include interstitial lung disease, cardiomyopathy, and QT interval prolongation. Monitoring and managing these side effects are crucial for patient safety and treatment efficacy.
